research scientist
Resume:
Hong Ma
**********@*****.***
Green Card Holder
Professional Summary
Highly skilled scientist who is proficient at extensive biotechnologies, eg., primary cell culture and cell line maintenance, PCR/ qPCR, primer design, DNA/RNA/protein/lipid extraction, Western Blot, AAV and lentivirus production and purification, guide RNA design for CRISPRi, cDNA library preparation for RNA-Seq, vector construction, ELISA, IHC, IF, Co-IP, mouse handling et al.
Organized, detail-oriented, devoted, work well both independently and in a team.
Work History
Boston University (Waxman Lab)-Research Scientist 06/2017 – Current
Concentrations: Knocked down long non-coding RNA in mouse liver using CRISPR-AAV system, studied the transcriptomic profile of constitutive androstane receptor-activated non-alcoholic fatty liver disease and hepatic cell carcinomas using RNAseq.
Developed a highly efficient method to produce, purify and titrate, rAAV8 and AAV-DJ.
Designed guide RNAs for multiple long noncoding RNAs, constructed gRNA into AAV vectors.
Delivered rAAV8 containing dSaCas9-KRAB and guide RNA into mouse liver through intravenous and intraperitoneal injection.
Confirmed the knockdown of long noncoding RNAs by q-PCR, prepare samples for single cell sequencing.
Cultured primary mouse hepatocytes to study liver-specific long noncoding RNA
Isolated RNA from liver chromatin pellet extract, soluble nuclear extract, total nuclear fraction, and cytoplasmic fraction, prepared cDNA library for RNA-Seq.
Studying the role of constitutive androstane receptor and Stat5b in the progression of fatty liver disease
Boston University (Salant lab) - Research Associate, Research Assistant Professor 12/2009 - 06/2017
Concentrations: Immune basis of membranous nephropathy (MN)
Purified Anti-PLA2R autoantibodies from sera of patients with MN and proved that it can bind and activate complement pathways in vitro.
Cooperate with clinical physicians to discover a new antigen (THSD7A) in MN.
Construct various domains of THSD7A and PLA2R into mammalian expression vector, and epitope mapping of anti-THSD7A and anti-PLA2R autoantibodies in MN.
Constructed full-length PLA2R and THSD7A lentiviral vectors, produced and purify lentivirus, and infected podocytes to establish stable PLA2R-expressing and THSD7A-expressing podocytes as in vitro models for the study of autoantibody functions.
Yale University (Ishibe lab) - Postdoctoral Associate 12/2007 - 12/2009
Concentrations: Define the mechanism of proteinuria by studying podocyte injury.
Used Cre-Lox and shRNA-lentivirus system to knockdown FAK in vivo and in vitro, demonstrated that inhibition of FAK activation prevents podocyte injury by inhibiting focal adhesion turnover and podocyte motibility. However, oral gauge of FAK inhibitor cannot ameliorate podocyte injury induced by LPS and rabbit anti-GBM
Studied tubular cell apoptosis, proliferation, and matrix gene expression in unilateral ureteral obstruction (UUO) mice (Met(fl/fl) HoxB7-Cre).
Tufts University (Yee Lab) - Postdoctoral Associate 12/2003 - 12/2007 Concentrations: Signaling pathway that regulate proliferation and invasiveness in breast cancer
Studied the cross-talk between wnt/β-catenin pathway and p38 MAPK pathway and their roles in breast cancer cells.
Investigated the cooperation of ErbB2 and TGF-beta in migration and invasion of mammary epithelial cells in 3D matrigel culture
Peking University (Tong/Zhang lab) - Ph. D. Candidate 08/1999 - 12/2002
Concentrations: Molecular mechanism of cellular aging and carcinogenesis.
Analyzed various biomarkers of cellular aging and established a multi-variable formula to assess the biological age of cultured cell
Microarray analysis of cellular aging.
Skills
Gene editing: sgRNA design, vector construction, AAV and lentivirus production and purification, virus transduction, virus delivery into mouse liver by intravenous injection or intraperitoneal injection.
Cell Culture: primary culture of mouse liver hepatocytes and kidney podocytes, 3D culture of epithelial cells, regular 2D cell culture.
Other Biotechnologies: q-PCR, primer design, cDNA library preparation, western blotting, immunofluorescence staining, immunochemistry, ELISA, immunoprecipitation, luciferase assay, protein affinity purification, subcutaneous tumor implantation, blood collection, transcardial perfusion, cryosectioning, paraffin sectioning
Computer and Data Analysis Skills: Microsoft Office package, GraphPad Prism, Image J, Primer Express, Primer3Plus, SnapGene, sgRNA design specific for CRISPRi/a
Education
DataCamp 2017
Online Courses, Data Analyst With R Track
Peking University, Beijing, P. R. China 2002
Ph.D in Biochemistry and Molecular Biology
Hornors
2015 CTSI Pilot Award for “Epitope mapping in thrombospondin type-1 domain-containing 7A (THSD7A) autoantibodies in idiopathic membranous nephropathy”
2014 CTSI Microarray Core Voucher Award for “Redefining Membranous Nephropathy by Autoantibody-specific Subclassification”.
2005 First Prize, Beijing Sci-Tech Achievement Award for “Establishment of the multi-variable biomarker of cellular aging” (2005 Medicine-1-004)
Select Presentations
1. Hong Ma, Christine Goldfarb, Kritika Karri, David J. Waxman. Functional impact of CRISPRi knockdown of TCPOBOP-responsive long non-coding RNA lnc5998 in mouse liver evaluated by single nuclei (sn)RNA-seq . Boston University GSI Symposium Abstract 2019.
2. Song YS, Ma H, Kumar S, Lu W, Beck LH Jr, Salant DJ. Expression of Thrombospondin Type 1 Domain-Containing 7A (THSD7A) in Developing Glomeruli. Kidney Week 2016.
3. Ma H, Beck LH Jr., Salant DJ. Autoantibodies Target Multiple Epitopes in THSD7A in Primary Membranous Nephropathy. Kidney Week 2015
4. Sandor D, Ma H, Salant DJ, Beck LH Jr. Identification of distinct dominant and subdominant humoral epitopes in PLA2R1. American Society of Nephrology, Kidney Week 2014
5. Ma H, Beck LH Jr., Salant DJ, Membranous Nephropathy-Associated Anti-phospholipase A2 Receptor IgG4 Autoantibodies Activate the Lectin Complement. American Society of Nephrology, Kidney Week 2011
Select Publications
1. Stoddard SV, Welsh CL, Palopoli MM, Stoddard SD, Aramandla MP, Patel RM, Ma H, Beck LH. Structure and function insights garnered from in silico modeling of the thrombospondin type-1 domain-containing 7A antigen. Proteins. 2019 Feb;87(2):136-145
2. Larsen CP, Trivin-Avillach C, Coles P, Collins AB, Merchant M, Ma H, Wilkey DW, Ambruzs JM, Messias NC, Cossey LN, Rosales IA, Wooldridge T, Walker PD, Colvin RB, Klein J, Salant DJ, Beck LH Jr. LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease. J Am Soc Nephrol. 2018 Feb;29(2):644-653
3. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014 Dec 11;371(24):2277-87.
4. Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy. Semin Nephrol. 2013 Nov;33(6):531-42.
5. Soda K, Balkin DM, Ferguson SM, Paradise S, Milosevic I, Giovedi S, Volpicelli-Daley L, Tian X, Wu Y, Ma H, Son SH, Zheng R, Moeckel G, Cremona O, Holzman LB, De Camilli P, Ishibe S. Role of dynamin, synaptojanin, and endophilin in podocyte foot processes. Clin Invest. 2012 Dec 3;122(12):4401-11.
6. Ma H, Togawa A, Soda K, Zhang J, Lee S, Ma M, Yu Z, Ardito T, Czyzyk J, Diggs L, Joly D, Hatakeyama S, Kawahara E, Holzman L, Guan JL, Ishibe S. Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J Am Soc Nephrol. 2010 Jul;21(7):1145-56
7. Ma H, Saenko M, Opuko A, Soda K, Togawa A, Cantley LG, and Ishibe S. Deletion of the Met Receptor in the collecting duct results in impaired repair following unilateral ureteral obstruction. Kidney Int. 2009 Oct;76(8):868-76
8. Ishibe S, Karihaloo A, Ma H, Zhang J, Marlier A, Mitobe M, Togawa A, Schmitt R, Czyczk J, Kashgarian M, Geller DS, Thorgeirsson SS, Cantley LG. Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development. 2009 Jan; 136(2):337-45.
9. Rieger-Christ KM, Ng L, Hanley RS, Durrani O, Ma H, Yee AS, Libertino JA, Summerhayes IC. Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer. 2005 Jun 20; 92(12):2153-9.
10. Ma H, Li RZ, Zhang ZY, Tong TJ. mRNA level of alpha-2-macroglobulin as an aging biomarker of human fibroblasts in culture. Exp Gerontol. 2004 Mar; 39(3):415-21.
11. Ma H, Zhang ZY, Tong TJ. Microarray analysis of premature induction in sub-lethally H2O2-treated young fibroblasts. Prog Biochem Biophys, 2003; 30(1), 72-7
12. Ma H, Zhang Z, Tong T. The effects of epidermal growth factor on gene expression in human fibroblasts. In Vitro Cell Dev Biol Anim. 2002 Sep; 38(8):481-6.
13. Ma H, Zhang ZY, Tong TJ. Effect of EGF on gene expression profile of human fibroblasts, Chinese Journal of Cellular Biology, 2002; 24(5):313-6
14. Ma H, Zhang ZY, Tong TJ. Biomarker of aging. Progress in Physiological Science. Sheng Li Ke Xue Jin Zhan. 2002 Jan; 33(1):65-8.
Contact this candidate